Journal ArticleUnknown
Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis
Author Affiliations
Ministry of Health and Family Welfare, Indian Council of Medical Research, World Health Organization - India, National Institute of Research in Tuberculosis, ...
Published InIndian Journal of Tuberculosis
Year2019
Citations31
Abstract
BACKGROUND India accounts for a quarter of the world's multidrug-resistant tuberculosis (MDR-TB); with less than 50% having successful treatment outcomes. Bedaquiline (BDQ) was approved for use under conditional access program in India in 2015. OBJECTIVE We evaluate the effectiveness, safety, and tolerability of a BDQ containing regimen used under field settings in India. METHOD Interim analysis of a prospective cohort of MDR-TB patients on a BDQ containing regimen at six sites in the country. RESULTS Six hundred and twenty MDR-TB patients [349 (56%) males; 554 (89%) between 18 and 50 years and 240 (39%) severely malnourished] were started on BDQ containing regimen between June 2016 and August 2017. There 354 (57%) patients had MDR-TB with additional drug resistance to fluoroquinolone…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.